{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:53:41Z","timestamp":1793969621475,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ophtha.2023.10.033","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:21:30Z","timestamp":1699024890000},"page":"422-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy"],"prefix":"10.1016","volume":"131","author":[{"given":"Rustum","family":"Karanjia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo A.","family":"Sadun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2023.10.033_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/brain\/awq276","article-title":"Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy","volume":"134","author":"Giordano","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ophtha.2023.10.033_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmg.2007.054270","article-title":"Inherited mitochondrial optic neuropathies","volume":"46","author":"Yu-Wai-Man","year":"2009","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ophtha.2023.10.033_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preteyeres.2003.10.003","article-title":"Mitochondrial dysfunction as a cause of optic neuropathies","volume":"23","author":"Carelli","year":"2004","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2023.10.033_bib4","author":"Barboni"},{"key":"10.1016\/j.ophtha.2023.10.033_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","article-title":"Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation","volume":"40","author":"Newman","year":"2020","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40123-022-00611-x","article-title":"Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A MT-ND4 Mutation","volume":"12","author":"Carelli","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ophtha.2023.10.033_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2019.11.014","article-title":"Demographics of a large international population of patients affected by Leber's hereditary optic neuropathy","volume":"127","author":"Poincenot","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2023.10.033_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41433-021-01535-9","article-title":"Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY study","volume":"36","author":"Yu-Wai-Man","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2023.10.033_bib9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.3201231","article-title":"Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy","volume":"242","author":"Wallace","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2023.10.033_bib10","doi-asserted-by":"crossref","first-page":"20065","DOI":"10.1073\/pnas.1217113109","article-title":"Mouse mtDNA mutant model of Leber hereditary optic neuropathy","volume":"109","author":"Lin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2023.10.033_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0014-5793(94)00971-6","article-title":"Functional alterations of the mitochondrially encoded ND4 subunit associated with Leber's hereditary optic neuropathy","volume":"352","author":"Degli Esposti","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ophtha.2023.10.033_bib12","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1074\/jbc.RA119.012094","article-title":"The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action","volume":"295","author":"Mitchell","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ophtha.2023.10.033_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s42003-020-1101-3","article-title":"The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats","volume":"3","author":"Allen","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.kint.2016.06.013","article-title":"Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury","volume":"90","author":"Szeto","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ophtha.2023.10.033_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1074248413508003","article-title":"Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia","volume":"19","author":"Brown","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2023.10.033_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.freeradbiomed.2018.12.031","article-title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","volume":"134","author":"Campbell","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ophtha.2023.10.033_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253849","article-title":"In\u00a0vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial","volume":"16","author":"Roshanravan","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2023.10.033_bib18","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial\u00a0myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2023.10.033_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcsm.12559","article-title":"A\u00a0randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy","volume":"11","author":"Karaa","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ophtha.2023.10.033_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","article-title":"Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial","volume":"26","author":"Butler","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ophtha.2023.10.033_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","article-title":"A\u00a0phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism","volume":"23","author":"Reid Thompson","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.ophtha.2023.10.033_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-world clinical experience with idebenone in the treatment of Leber hereditary optic neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib23","first-page":"433","article-title":"Long-term efficacy and safety of idebenone in patients with LHON in the subacute\/dynamic phase: results from the LEROS study","volume":"63","author":"Klopstock","year":"2022","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2023.10.033_bib24","article-title":"Impaired ganglion cell function objectively assessed by the photopic negative response in affected and asymptomatic members from Brazilian families with Leber's hereditary optic neuropathy","volume":"11","author":"Botelho","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10633-020-09784-x","article-title":"Photopic negative response using a handheld mini-ganzfeld stimulator in healthy adults: normative values, intra- and inter-session variability","volume":"142","author":"Berezovsky","year":"2021","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/pharmaceutics12111083","article-title":"Therapeutic approaches to treat mitochondrial diseases: \"one-size-fits-all\u201d and \"precision medicine\u201d strategies","volume":"12","author":"Bottani","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ophtha.2023.10.033_bib27","first-page":"141","article-title":"Novel therapeutic approaches for Leber's hereditary optic neuropathy","volume":"15","author":"Iyer","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.ophtha.2023.10.033_bib28","first-page":"13","article-title":"Further advances in the diagnosis and treatment of Leber's hereditary optic neuropathy - a review","volume":"66","author":"Tabacaru","year":"2022","journal-title":"Rom J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/aos.15153","article-title":"Clinical outcomes of treatment with idebenone in Leber's hereditary optic neuropathy in the Netherlands: a national cohort study","volume":"100","author":"van Everdingen","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.10.033_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/jcm10010151","article-title":"Changes in visual function and correlations with inner retinal structure in acute and chronic Leber's hereditary optic neuropathy patients after treatment with idebenone","volume":"10","author":"Pemp","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ophtha.2023.10.033_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ophtha.2023.10.033_bib32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023008023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023008023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:26:36Z","timestamp":1773393996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642023008023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0161642023008023"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.033","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}